NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.15 -2.84 (-3.69%) GOLD FUTURES
2,368.10 +22.30 (+0.95%) DOW
38,285.19 -401.13 (-1.04%) Bitcoin GBP
54,009.00 +770.70 (+1.45%)
MRK Jun 2024 124.000 call
| Previous close | 2.8100 |
| Open | 2.8000 |
| Bid | 4.1500 |
| Ask | 4.3500 |
| Strike | 124.00 |
| Expiry date | 2024-06-07 |
| Day's range | 2.1400 - 3.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 431 |
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
Simply Wall St.Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
BenzingaSummit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
